Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across multiple disease areas.
From L-R: Orionis chief strategy officer Giulio Draetta, CEO Niko Kley and chief data scientist Riccardo Sabatini
June 10, 2026 11:34 AM EDT
Novartis and Orionis strike second molecular glue deal for $40M upfront
Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
Novartis doubles down on molecular glue strategy
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal
Gilead and Merck's latest trial success and flop
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
Roche joins Californian Nurix oncology programme
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its…
